Rapidly progressive metaplastic breast cancer: a case report from Latin America


  • Metke Ricardo Department of Surgery,Hospital Universitario San Ignacio, Bogota, Colombia https://orcid.org/0000-0003-1940-741X
  • Torregrosa Lilian Department of Surgery, Hospital Universitario San Ignacio, Bogota, Colombia
  • Rubio Diego Department of Pathology, Hospital Universitario San Ignacio, Bogota, Colombia
  • Pinilla Paola Department of Oncology, Hospital Universitario San Ignacio, Bogota, Colombia
  • Lesmes Laura Department of Nursery, Hospital Universitario San Ignacio, Bogota, Colombia




Metaplastic breast cancer, Rapid progression, Surgery, Radiotherapy, Breast cancer treatment


Breast cancer is the most prevalent oncological pathology today; however, it is a broad pathology with different presentations according to the histological and molecular type. Metaplastic triple negative breast cancer is rare and has an aggressive presentation. We present this case given the low frequency of cases. We also present our management and outcomes. We present the case of an 85-year-old patient with an ulcerated exophytic mass in the right breast with progressive growth. The initial study was a biopsy, which evidence a triple negative invasive ductal breast carcinoma. Additional studies were negative for metastasis. The initial treatment was a surgical procedure, since the patient rejects initial management with chemotherapy. The pathology of the surgical piece confirms a metaplastic triple negative breast cancer. The patient has an adequate postoperative clinical evolution. Later she is taken to radiotherapy. At 3-month follow-up, the patient had adequate response. We present this case to create awareness of this type of cancer. This type of cancer must be known and suspected when dealing with a patient with triple negative breast cancer in order to carry out timely treatment, mainly with surgical management.



Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95-120.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

Rowe JJ. Biopsy Interpretation of the Breast. Am J Surgical Pathol. 2009;33:1579.

McMullen ER, Zoumberos NA, Kleer CG. Metaplastic Breast Carcinoma: Update on Histopathology and Molecular Alterations. Arch Pathol Lab Med. 2019;143(12):1492-6.

McAndrew NP, Hurvitz SA. Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. Hematol Oncol Clin North Am. 2023;37(1):103-15.

Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.

Yang X, Chen L, Shen Y. Breast Metaplastic Carcinoma with Osteosarcomatous Differentiation: A Case Report and literature Review. Clin Pathol. 2022;15:2632010X221118056.

Surenkok S, Tahberer E, Cinkaya A, Kodaz H, Deger A. Metaplastic breast cancer: A case report. J Pak Med Assoc. 2018;68(3):466-8.

Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888.

Rechsteiner A, Dietrich D, Varga Z. Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis. J Cancer Res Clin Oncol. 2022;36310301.






Case Reports